In this interview, Dr. Zaiba Malik talks with Dr. Rahul Khurana about the evolving standard of care for diabetic macular edema (DME). In fall 2012, the FDA approved ranibizumab (Lucentis) for DME, prompting a landmark shift from focal laser and off-label drug treatment to monthly anti-VEGF therapy. Dr. Khurana briefly reviews the primary outcomes from the RISE, RIDE, RESTORE, and DRCR.net studies that support the use of ranibizumab for DME and inform patient dosing regimens. He also discusses the potential role for laser monotherapy or combination therapies for edema lying outside the foveal center.

Financial Disclosures: Dr. Khurana is a paid consultant to Allergan, Genentech, iScience, and Regeneron.